PAA Research on X
Berkshire Hathaway’s TMHC deal is the third announced takeout of a public homebuilder this year, despite deeply negative housing-sector sentiment.
Sunday, May 31
Everything we published on this day.
2 stories
Berkshire Hathaway’s TMHC deal is the third announced takeout of a public homebuilder this year, despite deeply negative housing-sector sentiment.
Ivonescimab plus chemotherapy extended median overall survival by 4.2 months versus Tevimbra plus chemotherapy in HARMONI-6, challenging…